Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.89
WST's Cash to Debt is ranked lower than
57% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. WST: 0.89 )
Ranked among companies with meaningful Cash to Debt only.
WST' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.29 Max: 0.92
Current: 0.89
0.17
0.92
Equity to Asset 0.66
WST's Equity to Asset is ranked higher than
63% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. WST: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
WST' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.45 Max: 0.66
Current: 0.66
0.35
0.66
Interest Coverage 25.23
WST's Interest Coverage is ranked lower than
56% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. WST: 25.23 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.4  Med: 7.99 Max: 28.11
Current: 25.23
5.4
28.11
WACC vs ROIC
10.19%
12.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 13.04
WST's Operating margin (%) is ranked higher than
70% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.41 vs. WST: 13.04 )
Ranked among companies with meaningful Operating margin (%) only.
WST' s Operating margin (%) Range Over the Past 10 Years
Min: 8.21  Med: 10.07 Max: 13.04
Current: 13.04
8.21
13.04
Net-margin (%) 9.51
WST's Net-margin (%) is ranked higher than
69% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. WST: 9.51 )
Ranked among companies with meaningful Net-margin (%) only.
WST' s Net-margin (%) Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 9.52
Current: 9.51
5.91
9.52
ROE (%) 13.12
WST's ROE (%) is ranked higher than
74% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. WST: 13.12 )
Ranked among companies with meaningful ROE (%) only.
WST' s ROE (%) Range Over the Past 10 Years
Min: 9.65  Med: 13.52 Max: 17.69
Current: 13.12
9.65
17.69
ROA (%) 8.47
WST's ROA (%) is ranked higher than
76% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. WST: 8.47 )
Ranked among companies with meaningful ROA (%) only.
WST' s ROA (%) Range Over the Past 10 Years
Min: 5.09  Med: 6.34 Max: 16.94
Current: 8.47
5.09
16.94
ROC (Joel Greenblatt) (%) 21.21
WST's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. WST: 21.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
WST' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.75  Med: 17.48 Max: 44.98
Current: 21.21
12.75
44.98
Revenue Growth (3Y)(%) 1.60
WST's Revenue Growth (3Y)(%) is ranked lower than
58% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. WST: 1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
WST' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.9  Med: 6.6 Max: 17.8
Current: 1.6
-2.9
17.8
EBITDA Growth (3Y)(%) 3.20
WST's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. WST: 3.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
WST' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.3  Med: 7 Max: 16.8
Current: 3.2
-9.3
16.8
EPS Growth (3Y)(%) 6.80
WST's EPS Growth (3Y)(%) is ranked higher than
51% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. WST: 6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
WST' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -15  Med: 7.1 Max: 57.4
Current: 6.8
-15
57.4
GuruFocus has detected 4 Warning Signs with West Pharmaceutical Services Inc $WST.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

WST Guru Trades in Q1 2016

Columbia Wanger 317,164 sh (New)
Paul Tudor Jones 4,400 sh (New)
Jim Simons 514,200 sh (-0.06%)
Ken Fisher 1,228,363 sh (-0.95%)
Ron Baron 2,310,171 sh (-2.44%)
RS Investment Management 1,586,533 sh (-17.44%)
Ruane Cunniff 533,650 sh (-46.20%)
» More
Q2 2016

WST Guru Trades in Q2 2016

Paul Tudor Jones 14,000 sh (+218.18%)
Columbia Wanger 924,372 sh (+191.45%)
Ken Fisher 1,235,850 sh (+0.61%)
Ron Baron 2,274,371 sh (-1.55%)
Ruane Cunniff 443,019 sh (-16.98%)
RS Investment Management 1,253,102 sh (-21.02%)
Jim Simons 45,900 sh (-91.07%)
» More
Q3 2016

WST Guru Trades in Q3 2016

Jim Simons Sold Out
Ron Baron 2,258,479 sh (-0.70%)
Ken Fisher 1,222,462 sh (-1.08%)
Ruane Cunniff 424,467 sh (-4.19%)
Paul Tudor Jones 12,557 sh (-10.31%)
Columbia Wanger 781,437 sh (-15.46%)
» More
Q4 2016

WST Guru Trades in Q4 2016

Chuck Royce 23,000 sh (New)
Paul Tudor Jones Sold Out
Ken Fisher 1,170,631 sh (-4.24%)
Ron Baron 2,138,775 sh (-5.30%)
Ruane Cunniff 373,781 sh (-11.94%)
Columbia Wanger 606,983 sh (-22.32%)
» More
» Details

Insider Trades

Latest Guru Trades with WST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:STE, OTCPK:SAUHY, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI, NAS:PODD, NYSE:COO, OTCPK:ANSLY, NYSE:HAE, NYSE:RMD, NYSE:HYH, NAS:NXTM, OTCPK:TOPCF, NYSE:GKOS, NAS:MMSI, NAS:HOLX, NAS:ATRI, NAS:IRTC, NAS:LMNX » details
Traded in other countries:WPS.Germany,
West Pharmaceutical Services Inc is a manufacturer of components & systems for injectable drug delivery, plastic packaging, delivery system components. Its products include stoppers and seals for vials, prefillable syringe components and systems.

West Pharmaceutical Services Inc was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923. The Company is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. Majority of its business is conducted in healthcare markets. Its reportable segments are Packaging Systems and Delivery Systems. Packaging Systems develops, manufactures and sells primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of the Companys line of proprietary healthcare, administrative and advanced injection systems, including Daikyo CZ, SmartDose and other systems. Packaging Systems has three operating segments: the Americas, Europe and Asia Pacific. The Company competes with several companies across its product lines. Competition is based mainly on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost control programs across their entire operations. The design, development, manufacturing, marketing and labeling of certain of the Companys products and its customers products that incorporate its products are subject to regulation by governmental authorities in the United States, Europe and other countries, including the FDA and the European Medicines Agency.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services - Jan 30, 2017

Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about West Pharmaceutical Services Inc

Baron Asset Fund Comments on West Pharmaceutical Services Guru stock highlight
Shares of West Pharmaceutical Services, Inc. (NYSE:WST), a manufacturer of packaging components and delivery devices for injectable drugs, gained after reporting impressive quarterly financial results. Management provided solid guidance for 2017 and reaffirmed its goals for strong growth through 2020. We continue to believe that West can double its earnings over the next five years, driven by sales of higher margin packaging components and proprietary products to the pharmaceutical and biotechnology industries. Read more...
Baron Funds Comments on West Pharmaceutical Services Guru stock highlight
West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 43.47
WST's P/E(ttm) is ranked lower than
71% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.87 vs. WST: 43.47 )
Ranked among companies with meaningful P/E(ttm) only.
WST' s P/E(ttm) Range Over the Past 10 Years
Min: 12.28  Med: 22.72 Max: 64.85
Current: 43.47
12.28
64.85
Forward P/E 33.11
WST's Forward P/E is ranked lower than
80% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.15 vs. WST: 33.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 43.47
WST's PE(NRI) is ranked lower than
74% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. WST: 43.47 )
Ranked among companies with meaningful PE(NRI) only.
WST' s PE(NRI) Range Over the Past 10 Years
Min: 12.28  Med: 22.79 Max: 64.85
Current: 43.47
12.28
64.85
Price/Owner Earnings (ttm) 99.27
WST's Price/Owner Earnings (ttm) is ranked lower than
85% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.26 vs. WST: 99.27 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
WST' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 19.16  Med: 38.86 Max: 173.32
Current: 99.27
19.16
173.32
P/B 5.45
WST's P/B is ranked lower than
74% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. WST: 5.45 )
Ranked among companies with meaningful P/B only.
WST' s P/B Range Over the Past 10 Years
Min: 1.74  Med: 2.9 Max: 5.67
Current: 5.45
1.74
5.67
P/S 4.13
WST's P/S is ranked lower than
60% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. WST: 4.13 )
Ranked among companies with meaningful P/S only.
WST' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.56 Max: 4.29
Current: 4.13
1.02
4.29
PFCF 64.85
WST's PFCF is ranked lower than
81% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.37 vs. WST: 64.85 )
Ranked among companies with meaningful PFCF only.
WST' s PFCF Range Over the Past 10 Years
Min: 18.49  Med: 45.74 Max: 381.09
Current: 64.85
18.49
381.09
POCF 28.48
WST's POCF is ranked lower than
71% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.55 vs. WST: 28.48 )
Ranked among companies with meaningful POCF only.
WST' s POCF Range Over the Past 10 Years
Min: 7.55  Med: 12 Max: 29.57
Current: 28.48
7.55
29.57
EV-to-EBIT 31.05
WST's EV-to-EBIT is ranked lower than
65% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.36 vs. WST: 31.05 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 18.8 Max: 53.3
Current: 31.05
11.2
53.3
EV-to-EBITDA 21.29
WST's EV-to-EBITDA is ranked lower than
67% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.65 vs. WST: 21.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 11.9 Max: 27.6
Current: 21.29
7.6
27.6
PEG 6.28
WST's PEG is ranked lower than
80% of the 56 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. WST: 6.28 )
Ranked among companies with meaningful PEG only.
WST' s PEG Range Over the Past 10 Years
Min: 1.01  Med: 2.04 Max: 50.27
Current: 6.28
1.01
50.27
Shiller P/E 60.32
WST's Shiller P/E is ranked lower than
74% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.26 vs. WST: 60.32 )
Ranked among companies with meaningful Shiller P/E only.
WST' s Shiller P/E Range Over the Past 10 Years
Min: 19.08  Med: 32.73 Max: 62.78
Current: 60.32
19.08
62.78
Days Inventory 69.65
WST's Days Inventory is ranked higher than
85% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.69 vs. WST: 69.65 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 32.79  Med: 64.01 Max: 70.1
Current: 69.65
32.79
70.1
Days Sales Outstanding 50.67
WST's Days Sales Outstanding is ranked higher than
74% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.60 vs. WST: 50.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 47.3 Max: 50.67
Current: 50.67
41.76
50.67
Days Payable 35.85
WST's Days Payable is ranked lower than
71% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.38 vs. WST: 35.85 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 38.65 Max: 46.32
Current: 35.85
29.33
46.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.60
WST's Dividend Yield is ranked lower than
79% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. WST: 0.60 )
Ranked among companies with meaningful Dividend Yield only.
WST' s Dividend Yield Range Over the Past 10 Years
Min: 0.57  Med: 1.24 Max: 2.01
Current: 0.6
0.57
2.01
Dividend Payout 0.26
WST's Dividend Payout is ranked higher than
79% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. WST: 0.26 )
Ranked among companies with meaningful Dividend Payout only.
WST' s Dividend Payout Range Over the Past 10 Years
Min: 0.23  Med: 0.27 Max: 0.35
Current: 0.26
0.23
0.35
Dividend Growth (3y) 8.40
WST's Dividend Growth (3y) is ranked lower than
63% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.20 vs. WST: 8.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
WST' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 5.2  Med: 6.5 Max: 8.4
Current: 8.4
5.2
8.4
Forward Dividend Yield 0.63
WST's Forward Dividend Yield is ranked lower than
83% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. WST: 0.63 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.85
WST's Yield on cost (5-Year) is ranked lower than
77% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.99 vs. WST: 0.85 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
WST' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.81  Med: 1.76 Max: 2.85
Current: 0.85
0.81
2.85
3-Year Average Share Buyback Ratio -1.40
WST's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. WST: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: -1.3 Max: 4.8
Current: -1.4
-4
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 93.79
WST's Price/Net Current Asset Value is ranked lower than
99.99% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.51 vs. WST: 93.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WST' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0  Med: 2007.33 Max: 2007.33
Current: 93.79
0
2007.33
Price/Tangible Book 5.47
WST's Price/Tangible Book is ranked lower than
53% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.64 vs. WST: 5.47 )
Ranked among companies with meaningful Price/Tangible Book only.
WST' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.07  Med: 3.17 Max: 6.87
Current: 5.47
2.07
6.87
Price/Projected FCF 3.97
WST's Price/Projected FCF is ranked lower than
80% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. WST: 3.97 )
Ranked among companies with meaningful Price/Projected FCF only.
WST' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.27  Med: 2.24 Max: 4.04
Current: 3.97
1.27
4.04
Price/DCF (Earnings Based) 3.76
WST's Price/DCF (Earnings Based) is ranked lower than
90% of the 20 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. WST: 3.76 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.65
WST's Price/Median PS Value is ranked lower than
91% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. WST: 2.65 )
Ranked among companies with meaningful Price/Median PS Value only.
WST' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 0.86 Max: 2.69
Current: 2.65
0.54
2.69
Price/Peter Lynch Fair Value 7.95
WST's Price/Peter Lynch Fair Value is ranked lower than
97% of the 35 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. WST: 7.95 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WST' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.98  Med: 1.73 Max: 13.06
Current: 7.95
0.98
13.06
Price/Graham Number 3.25
WST's Price/Graham Number is ranked lower than
61% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. WST: 3.25 )
Ranked among companies with meaningful Price/Graham Number only.
WST' s Price/Graham Number Range Over the Past 10 Years
Min: 1.04  Med: 1.72 Max: 3.55
Current: 3.25
1.04
3.55
Earnings Yield (Greenblatt) (%) 3.19
WST's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. WST: 3.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WST' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 5.3 Max: 8.9
Current: 3.19
1.9
8.9
Forward Rate of Return (Yacktman) (%) 6.65
WST's Forward Rate of Return (Yacktman) (%) is ranked lower than
62% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.86 vs. WST: 6.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WST' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.7  Med: 10.4 Max: 22.2
Current: 6.65
-3.7
22.2

More Statistics

Revenue (TTM) (Mil) $1,509
EPS (TTM) $ 1.92
Beta1.08
Short Percentage of Float2.57%
52-Week Range $55.23 - 88.30
Shares Outstanding (Mil)73.18

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 2.51
EPS w/o NRI ($) 2.51
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for WST

Headlines

Articles On GuruFocus.com
Baron Asset Fund Comments on West Pharmaceutical Services Jan 30 2017 
Baron Asset Fund 4th Quarter Shareholder Letter Jan 30 2017 
Baron Funds Comments on West Pharmaceutical Services Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Weekly CEO Buys Highlight: WST, PHII, CLMS, CSBK, AMRC May 26 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Is Cooper Companies' Upward Trend Likely to Go On? Mar 25 2014 
Illumina Inc: How Long Can a Miracle Go On? Feb 07 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
The Best Dividends on April 16, 2012 Apr 13 2012 

More From Other Websites
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: 2016 By the Numbers : February 21,... Feb 21 2017
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 17 2017
Edited Transcript of WST earnings conference call or presentation 16-Feb-17 2:00pm GMT Feb 16 2017
West Pharmaceutical Services Inc Earnings Call scheduled for 9:00 am ET today Feb 16 2017
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 16 2017
West Pharmaceutical misses Street 4Q forecasts Feb 16 2017
West Pharmaceutical misses Street 4Q forecasts Feb 16 2017
Q4 2016 West Pharmaceutical Services Inc Earnings Release - Before Market Open Feb 16 2017
West Announces Fourth-Quarter and Full-Year 2016 Results and Announces Quarterly Dividend Feb 16 2017
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX Feb 15 2017
West to Host Fourth-Quarter and Full-Year 2016 Conference Call Feb 02 2017
West Introduces LyoSeal® Instant Sealing Solution and NovaGuard® SA Pro Safety System at... Feb 01 2017
Baron Asset Fund Comments on West Pharmaceutical Services Jan 30 2017
Baron Asset Fund 4th Quarter Shareholder Letter Jan 30 2017
West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : January 25, 2017 Jan 25 2017
West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bearish Manner : WST-US :... Jan 24 2017
ETFs with exposure to West Pharmaceutical Services, Inc. : January 20, 2017 Jan 20 2017
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Jan 11 2017
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 06 2017
West to Present at J.P. Morgan Healthcare Conference Dec 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)